King & Spalding Partner David Farber called for amending Medicare and Medicaid statutes so that unapproved treatments can be reimbursed for terminally ill patients who have exhausted all other options.

CBER director said unlicensed stem cell clinics often report adverse events not made public, which is a concern under Right To Try.

Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.

Brainstorm’s president and CEO Chaim Lebovits talks to Scrip about the company’s progress with personalized stem cell therapy NurOwn in ALS and what the future holds for cell therapy options in neurology.